Fifth Circuit upholds FTC’s Impax decision

There is substantial evidence to support the Federal Trade Commission’s conclusion that a pay-for-delay settlement between Endo Pharmaceuticals and Impax Laboratories violated federal antitrust law, the US Court of Appeals for the Fifth Circuit has ruled.